Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call Transcript
Good day, and welcome to the Fate Therapeutics ASH Update Call. (Operator Instructions)
As a reminder, this call may be recorded. I would now like to turn the call over to Scott Wolchko. You may begin.
Thank you. Good morning. This is Scott Wolchko, President and CEO of Fate Therapeutics. Thank you all for joining us this morning to discuss our off-the-shelf iPSC-derived NK cell programs, FT516 and FT596, for the treatment of B-cell lymphoma. Please note that during our discussion, our comments will include forward-looking statements that involve risks and uncertainties. These factors are detailed in our SEC filings, and I refer you to the most recent Form 10-Q filed with the SEC on November 4 for full disclosure of these risks and uncertainties. I'm pleased to be joined today by Dr. Wayne Chu, our Senior Vice President of Clinical Development; Dr. Sarah Cooley, our Senior Vice President of Clinical Translation; and Dr. Bob Valamehr, our Chief Research and Development
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |